Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841343 · ClinicalTrials.gov registry record
Triamcinolone Packing Following Endoscopic Sinus Surgery
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 22
- Enrollment target
NCT04841343: Completed study, sponsored by University of California, Los Angeles.
NCT04841343 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04841343 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. A 2012 systematic review favored spacers compared to no spacers, with a follow up 2013 systematic review finding no difference between the use of absorbable and non-absorbable spacers. This review, however, noted that steroidal spacers may reduce middle meatus scarring and adhesions. More recent data has shown the effectiveness of steroid releasing middle meatus implants in preventing middle turbinate lateralization, reducing synechiae formation, and reducing revision surgery. However, these stents are costly, and may result in excess crusting postoperatively, which limits their use in some settings. Another study investigated the use of steroid-impregnated absorbable packing materials, and demonstrated the safety and utility of this method of middle meatus packing. However, a limitation to this study was overall low enrollment with only 19 total patients enrolled. The purpose of this project is to add to the existing body of evidence regarding middle meatus spacers, by studying the impact of steroid impregnated, bioabsorbable hemostatic packing (Hemopore®, Stryker) on postoperative visualization and scar formation.
Primary Outcome
Assessment of inflammation, crusting, polyps, edema in sinus; Scale from 0 to 2, with higher scores meaning worse outcome
Interventions
- DRUG Triamcinolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2022-09-30 |
What the finished NCT04841343 record still lists
NCT04841343 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Triamcinolone is the first listed.
NCT04841343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04841343 about?
NCT04841343 is a clinical study titled "Triamcinolone Packing Following Endoscopic Sinus Surgery". Endoscopic sinus surgery (ESS) is a well-established treatment strategy for medically refractory chronic rhinosinusitis. Middle meatus spacers are currently used following ESS to prevent scarring, synechiae formation, and middle turbinate lateralization. A 2012 systematic review favored spacers comp...
What is the current status of trial NCT04841343?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2021-01-29. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT04841343?
The interventions under investigation include: Triamcinolone (DRUG).
Who is sponsoring clinical trial NCT04841343?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI